Relapse
Of a total of 49 responders in the eltrombopag group, 10.2% relapsed
(n=5) compared with 4.1% (n=2) who relapsed in the control group (Table
2). The times to relapse were 5, 9, 11, 12, and 29 months after IST in
the eltrombopag group, respectively. Among the relapsed cases of the
eltrombopag group, one reached CR after HSCT, and the other four
continued oral full-dose CSA with added stanozolol, eltrombopag and
traditional Chinese Medicine, and achieved CR (n=1) or partial response
(n=3). In the control group, the times to relapse were 10 months and 24
months after IST, respectively. Among the relapsed cases of the control
group, one reached CR after HSCT, and the other continued oral full-dose
cyclosporine with added stanozolol, showing recovery CR (n=1). There was
no significant difference in relapse rate between the two groups
(P=0.703).